Evaluation of Sentinel Lymph Node Biopsy After Primary Chemotherapy as Part of De-Escalation of Breast Cancer Treatment
Background: Sentinel lymph node biopsy (SLNB) after primary chemotherapy for node-positive breast cancer patients has been gaining popularity as part of the de-escalation of treatment. Aim: The 1ry aim was to assess the surgical outcome of node-positive patients who received primary chemotherapy fo...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Kasr Al-Ainy Center of Clinical Oncology and Nuclear Medicine
2021-12-01
|
| Series: | Research in Oncology |
| Subjects: | |
| Online Access: | https://resoncol.journals.ekb.eg/article_214163_82c5c760159d61944e03f370bb8a9919.pdf |
| _version_ | 1819280789656829952 |
|---|---|
| author | Mohamed I. AbdelAziz Sherif Monib |
| author_facet | Mohamed I. AbdelAziz Sherif Monib |
| author_sort | Mohamed I. AbdelAziz |
| collection | DOAJ |
| description | Background: Sentinel lymph node biopsy (SLNB) after primary chemotherapy for node-positive breast cancer patients has been gaining popularity as part of the de-escalation of treatment.
Aim: The 1ry aim was to assess the surgical outcome of node-positive patients who received primary chemotherapy followed by SLNB. A 2ry aim was to determine the rate of sentinel lymph node identification using the patent blue dye only technique.
Methods: A prospective study that included 86 patients with invasive breast cancer and axillary lymph nodes metastasis as proved by ultrasound scan guided core biopsy. Following the completion of primary chemotherapy, sentinel lymph node biopsy was carried out for all patients at the time of breast surgery using the patent blue dye technique. Patients with negative SLNB underwent no further axillary procedure. Completion of axillary lymph node clearance was performed for positive SLNB patients.
Results: The sentinel lymph node identification rate using the patent blue dye directed technique was 79%. Sixty-seven (78%) patients underwent wide local excision, and 35% did not need completion of axillary lymph node clearance due to downstaging following primary chemotherapy.
Conclusions: Sentinel lymph node biopsy following primary chemotherapy for invasive breast cancer appears to be a safe, reliable technique, with an acceptable identification rate, even when using the patent blue dye technique only. |
| first_indexed | 2024-12-24T00:49:23Z |
| format | Article |
| id | doaj.art-ca9faddfd73845d7a6d4178116446585 |
| institution | Directory Open Access Journal |
| issn | 2357-0687 2357-0695 |
| language | English |
| last_indexed | 2024-12-24T00:49:23Z |
| publishDate | 2021-12-01 |
| publisher | Kasr Al-Ainy Center of Clinical Oncology and Nuclear Medicine |
| record_format | Article |
| series | Research in Oncology |
| spelling | doaj.art-ca9faddfd73845d7a6d41781164465852022-12-21T17:23:38ZengKasr Al-Ainy Center of Clinical Oncology and Nuclear MedicineResearch in Oncology2357-06872357-06952021-12-01172606510.21608/resoncol.2021.72839.1140Evaluation of Sentinel Lymph Node Biopsy After Primary Chemotherapy as Part of De-Escalation of Breast Cancer TreatmentMohamed I. AbdelAziz0https://orcid.org/0000-0001-6239-8147Sherif Monib1General Surgery Department, Fayoum University Hospital, Fayoum, EgyptSt. Albans Hospital Breast Unit, West Hertfordshire Hospitals NHS Trust, Hertfordshire, United KingdomBackground: Sentinel lymph node biopsy (SLNB) after primary chemotherapy for node-positive breast cancer patients has been gaining popularity as part of the de-escalation of treatment. Aim: The 1ry aim was to assess the surgical outcome of node-positive patients who received primary chemotherapy followed by SLNB. A 2ry aim was to determine the rate of sentinel lymph node identification using the patent blue dye only technique. Methods: A prospective study that included 86 patients with invasive breast cancer and axillary lymph nodes metastasis as proved by ultrasound scan guided core biopsy. Following the completion of primary chemotherapy, sentinel lymph node biopsy was carried out for all patients at the time of breast surgery using the patent blue dye technique. Patients with negative SLNB underwent no further axillary procedure. Completion of axillary lymph node clearance was performed for positive SLNB patients. Results: The sentinel lymph node identification rate using the patent blue dye directed technique was 79%. Sixty-seven (78%) patients underwent wide local excision, and 35% did not need completion of axillary lymph node clearance due to downstaging following primary chemotherapy. Conclusions: Sentinel lymph node biopsy following primary chemotherapy for invasive breast cancer appears to be a safe, reliable technique, with an acceptable identification rate, even when using the patent blue dye technique only.https://resoncol.journals.ekb.eg/article_214163_82c5c760159d61944e03f370bb8a9919.pdfbreast cancersentinel lymph nodeneoadjuvant chemotherapypatent blue dye |
| spellingShingle | Mohamed I. AbdelAziz Sherif Monib Evaluation of Sentinel Lymph Node Biopsy After Primary Chemotherapy as Part of De-Escalation of Breast Cancer Treatment Research in Oncology breast cancer sentinel lymph node neoadjuvant chemotherapy patent blue dye |
| title | Evaluation of Sentinel Lymph Node Biopsy After Primary Chemotherapy as Part of De-Escalation of Breast Cancer Treatment |
| title_full | Evaluation of Sentinel Lymph Node Biopsy After Primary Chemotherapy as Part of De-Escalation of Breast Cancer Treatment |
| title_fullStr | Evaluation of Sentinel Lymph Node Biopsy After Primary Chemotherapy as Part of De-Escalation of Breast Cancer Treatment |
| title_full_unstemmed | Evaluation of Sentinel Lymph Node Biopsy After Primary Chemotherapy as Part of De-Escalation of Breast Cancer Treatment |
| title_short | Evaluation of Sentinel Lymph Node Biopsy After Primary Chemotherapy as Part of De-Escalation of Breast Cancer Treatment |
| title_sort | evaluation of sentinel lymph node biopsy after primary chemotherapy as part of de escalation of breast cancer treatment |
| topic | breast cancer sentinel lymph node neoadjuvant chemotherapy patent blue dye |
| url | https://resoncol.journals.ekb.eg/article_214163_82c5c760159d61944e03f370bb8a9919.pdf |
| work_keys_str_mv | AT mohamediabdelaziz evaluationofsentinellymphnodebiopsyafterprimarychemotherapyaspartofdeescalationofbreastcancertreatment AT sherifmonib evaluationofsentinellymphnodebiopsyafterprimarychemotherapyaspartofdeescalationofbreastcancertreatment |